Graphene FET sensors for Alzheimer’s disease protein biomarker clusterin detection by Bungon, Theodore et al.
  
Proceedings 2020, 4, x; doi: FOR PEER REVIEW www.mdpi.com/journal/proceedings 
Proceedings 
Graphene FET Sensors for Alzheimer’s Disease 
Protein Biomarker Clusterin Detection † 
Theodore Bungon 1, Carrie Haslam 1, Benjamin O’Driscoll 1, Toby Whitley 1, Paul Davey 1, 
Giuliano Siligardi 2, Jerome Charmet 3 and Shakil A. Awan 1,* 
1 Wolfson Nanomaterials and Devices Laboratory, School of Engineering, Computing and Mathematics, 
Faculty of Science and Engineering, University of Plymouth, Drake Circus, Plymouth, Devon, PL4 8AA, 
UK; theodore.bungon@plymouth.ac.uk (T.B.); carrie.haslam@plymouth.ac.uk (C.H.); 
benjamin.odriscoll@plymouth.ac.uk (B.O.); toby.whitley@plymouth.ac.uk (T.W.); 
paul.davey@plymouth.ac.uk (P.D.) 
2 Diamond Light Source, Rutherford Appleton Laboratory, Oxfordshire, OX11 0DE, UK; 
siligardi.giuliano@diamond.ac.uk 
3 Institute of Digital Healthcare, WMG, University of Warwick, Coventry CV4 7AL, UK; 
j.charmet@warwick.ac.uk 
* Correspondence: shakil.awan@plymouth.ac.uk; Tel.: +44-(0)1752-586-325 
† Presented at the 1st International Electronic Conference on Biosensors, 2–17 November 2020; Available 
online: https://iecb2020.sciforum.net/. 
Published: date 
Abstract: We report on the fabrication and characterisation of graphene field-effect transistor 
(GFET) biosensors for detecting Clusterin, a prominent protein biomarker of Alzheimer’s disease 
(AD). The GFET sensors were fabricated on Si/SiO2 substrate using photolithographic patterning 
and metal lift-off techniques with evaporated chromium and sputtered gold contacts. Raman 
Spectroscopy was performed on the devices to determine the quality of the graphene. The GFETs 
were annealed to improve their performance before the channels were functionalized by 
immobilising the graphene surface with linker molecules and anti-clusterin antibody. Concentration 
of linker molecules was also independently verified by absorption spectroscopy using the highly 
collimated micro beam-light of Diamond B23 beamline. The detection was achieved through the 
binding reaction between the antibody and varying concentrations of Clusterin antigen from 1 
pg/mL to 100 pg/mL, as well as specificity tests using human chorionic gonadotropin (hCG), a 
glycoprotein risk biomarker of certain cancers. The GFETs were characterized using direct current 
(DC) 4-probe electrical resistance (4-PER) measurements, which demonstrated a limit of detection 
of the biosensors to be ~ 210 fg/mL. Thus, we have successfully fabricated a promising GFET 
biosensor for detection of Clusterin, the developed GFET biosensors are entirely generic and also 
have the potential to be applied to a variety of other disease detection applications such as 
Parkinson’s, cancer and cardiovascular. 
Keywords: graphene; FET; biosensor; diagnosis; 4-probe electrical detection; Clusterin; Alzheimer’s 
disease; dementia; protein biomarkers; hCG; absorbance spectroscopy 
 
1. Introduction 
Graphene, a single atomic plane of carbon, was considered to be thermodynamically unstable 
until 16 years ago. In 2004, Novoselov et al. [1] experimentally demonstrated that graphene can exist 
in the free state at room temperature, and that it is stable with a single layer of graphene being a zero-
gap semiconductor. The monolayer of sp2 bonded carbon atoms is tightly packed into a two-
dimensional (2D) sheet arranged in a honeycomb lattice. Graphene has the potential to advance many 
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technological areas because of its outstanding material properties such as its high carrier mobility [1–
4], current carrying capacity [5], thermal conductivity at room temperature [6], optical properties [7] 
and mechanical stability [8]. It is being researched for various applications such as high-speed 
electronics [9,10], optoelectronics [11], solar cells [12] energy storage [13], electrochemical resonators 
[14], composites [15] and biosensors [16,17].  
Graphene is ideally suited to applications in biosensing due to its large surface-to-volume ratio, 
biocompatibility, chemical stability, ease of surface functionalization, field effect-based ambipolar 
transport of electrons and holes and excellent electrical conductivity [18], which are highly beneficial 
for good sensor performance such as increased sensitivities and lower limits of detection (LOD). 
Among the many graphene-based biosensor applications, graphene field-effect transistors (GFETs) 
are widely regarded a promising platform for biosensing. The graphene channel in GFETs is typically 
exposed to the biological environment and is able to detect the presence of biomolecules electrically, 
based on resistance/conductance change caused by the binding of receptor molecules with a given 
antigen biomarker (enzymes, proteins, peptides, DNA, etc). [17,19,20]. GFET is a powerful biosensing 
platform due to its relative simplicity in sensor preparation but also signal-to-noise ratio, low cost, 
portability and easy integration with a range of existing electronic systems. GFETs consume less 
energy, can be scaled down and can operate higher frequencies making them a flexible platform for 
biosensing [1,21]. Such GFETs biosensors are being researched on extensively for early diagnosis of 
not only Alzheimer’s disease but also a variety of other disease diagnosis such as Parkinson’s, cancer 
and cardiovascular. 
Here, we report on the detection of Clusterin, a prominent protein biomarker of Alzheimer’s 
disease (AD) using both electrical and B23 absorption spectroscopy approaches. AD is a sub-type of 
dementia responsible for around 60-70% of cases in neurodegenerative diseases. There are 
approximately 54 million people currently living with dementia worldwide and this number is 
expected to rise to 130 million by 2050, and an estimated 9.9 million people will develop the disease 
every year [22]. AD is an incurable and long-term neurodegenerative disease that progressively 
worsens over time. It is believed to be caused by abnormal build-up of proteins in and around the 
brain. Tests have revealed deposits of protein around the extracellular and intracellular 
compartments of a post-mortem AD brain, the intracellular deposits were made up of filaments of 
hyperphosphorylated tau protein [23]. Evidence has shown that neurofibrillary tangles (NFTs), 
consisting of hyperphosphorylated tau, are present within the neurons of AD patients; NFTs cause 
disruption of normal communication between neurons [24]. While the extracellular deposits also 
known as amyloid plagues are most commonly found in the neocortex (responsible for sensory 
perception, reasoning, conscious thoughts, generation of motor commands and language in human). 
The neocortex consists of 4-kDa polypeptide known as the β-amyloid (Aβ) [25,26]. Research has 
shown considerable evidence that neurodegeneration that occurs in AD patients is as a result of the 
accumulation and aggregation of Aβ. Aβ plaques are formed within the medial temporal lobe and 
also within the cerebral cortex of the brain tissue. This Aβ formation is attributed to the abnormal 
metabolism β-amyloid precursor protein (APP) [27]. The Aβ plaques and NFTs develop over a very 
long period of time and leads to death of nerve cells and loss of brain tissues. Clusterin (CLU), also 
known as apolipoprotein-J, is a glycoprotein found in various tissues and bodily fluids [28], and it 
functions as an extracellular chaperone [29]. Increased levels of Clusterin have been found in the 
frontal cortex and hippocampus of post-mortem AD brain tissue [30,31]. It was demonstrated that 
CLU is strongly associated to soluble Aβ in the cerebral spinal fluid (CSF) [32], and it can either 
prevent the aggregation of Aβ or increase its solubility [33]. It regulates the formation and toxicity of 
Aβ fibril, and also aids in conveying Aβ across the blood–brain barrier. Clusterin has a molecular 
weight of 80 kDa and is comprised of 449 amino acids [34,35], two 40 kDa subunits of α and β 
connected by five disulphide bond motif [36]. Clusterin plays an important role in the progression of 
AD and it has been identified as one of the key biomarkers of AD [37]. It was experimentally shown 
that Clusterin was elevated about 40% above nondemented controls in the brain of AD patients. 
[31,38]. Currently, diagnosis of AD can take up to two years involving a range of different tests such 
as computer tomography (CT), magnetic resonance imaging (MRI) and Positron emission 
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tomography (PET), neurological evaluation, cognitive and neuropsychological test [39]. Therefore, 
the need for a fast, low-cost, accurate, non-invasive, and portable means of diagnosing Alzheimer’s 
disease at an early stage is of high importance. Thus, GFET biosensors offer a unique route towards 
the development of vitally needed diagnostic platform for AD. 
2. Materials and Methods 
2.1. Materials 
A monolayer graphene produced by chemical vapour deposition (CVD) method on a 300 nm 
Si/SiO2 substrate was supplied from LG Electronics Inc. (Gangseo-gu, Seoul, Korea). The chemicals 
used for the GFET fabrication were photoresist, lift-off resist (LoR), Microposit developer and 
Microposit remover, purchased from A-Gas Electronic Materials (Warwickshire, UK).  
Recombinant human clusterin protein and anti-clusterin antibody were purchased from Abcam 
(Cambridge, UK). Linker molecule 1-pyrenebutanoic acid succinimidyl ester (Pyr-NHS), bovine 
serum albumin (BSA) blocking solution and Phosphate-Buffered Saline (PBS) were purchased from 
Sigma Aldrich (Dorset, UK). All measurements were performed at room temperature and pH of 7.4. 
The quality of graphene was evaluated using an XPLORA Raman spectroscopy system 
(HORIBA, Northampton, UK). All measurements on the XPLORA system were performed at a 
wavelength of 532 nm, with ~ 4 mW of incident power and a grating of 1200T. The XPLORA Raman 
system was interfaced with an OLYMPUS BX41 microscope (Shinjuku, Japan).  
The electrical characterisation of the GFETs was performed under ambient conditions using a 
Keysight B1500A semiconductor device parameter analyser interfaced to a MPS150 probe station 
(Cascade Microtech, Thiendorf, Germany). The 4-probe current–voltage measurements (ID–VD and 
ID–VG) were acquired as a function of gate voltage (VG) from −100 V to +100 V with ID–VD curves from 
−50 mV to +50 mV with a 100µA compliance. The ID–VD and ID–VG curves were measured at each 
functionalisation stage. 
All absorption spectroscopy experiments were performed on Beamline B23 at Diamond Light 
Source (Oxfordshire, UK) over the 180 – 400 nm wavelength range, using a wavelength increment of 
1nm, with cell path length of 1mm and at room temperature ~ 22 °C [40]. 
Circular dichroism (CD) is a versatile spectroscopic technique which 
2.2. Fabrication of the Graphene FETs 
The GFET sensors were fabricated on a p++ Si/SiO2 substrate through the processes of 
photolithographic patterning and metal lift-off techniques with evaporated chromium and sputtered 
gold contacts. There are two major stages in the fabrication process, the first stage involves forming 
the graphene channel whereas the second stage involves forming the source, drain and voltage 
electrodes. Figure 1 shows a representation of the fabrication process. 
 
Figure 1. Overview of the processes for Graphene field-effect transistor (GFET) fabrication; (a) layer 
of graphene on Si/SiO2 substrate; (b) lift-off resist (LoR) deposition; (c) photoresist (PR) deposition; 
(d) sample below the photolithography mask aligner for UV exposure; (e) etching of graphene 
channels and chemical developing process; (f) final stage of metallic Cr and Au deposition. 
Commented [M2]: Please check the format of this sentence. 
Proceedings 2020, 4, x FOR PEER REVIEW 4 of 16 
 
The formation of the graphene channels on the Si/SiO2 substrate involves dicing the samples into 
sizes of 1cm x 1cm chips before spin-coating the samples with lift-off resist (LoR) at 3000 revolutions-
per-minute (rpm) for 30 s. The samples are then pre-baked in a fan oven at 175 °C for 15 min. Pre-
baking the samples solidifies the LoR as it eases in lifting off the photoresist (PR) while protecting the 
graphene channels formed. The next step is spin-coating the samples with a layer of positive 
photoresist (PR) at 3000 rpm for 30 s and then post-baking on a hotplate at 100 °C for 60 s. The post-
bake step is to solidify the PR and remove any solvents on the samples. The samples are then 
positioned in a mask-aligner under a patterned mask for creating the graphene channels, and exposed 
to ultra-violet (UV) radiation for 25 s. The samples are then rinsed in a chemical developer mixed 
with di-ionized water (20 mL developer mixed with 30mL di-ionized water), until the graphene 
channels are visible under a microscope. There is always residue of PR/PMMA on the sample at this 
stage, which degrades the quality of the graphene, which can be reduced by post-baking the samples 
on a hotplate at 180 °C for 8 min under deep ultraviolet (DUV) light of 254 nm. The DUV dissociates 
the bonds between PR/PMMA and graphene and reduces contact resistance of the sample. 
Next, the samples are transferred into a sputtering machine for Ar plasma etching. The 
unprotected graphene samples (not protected by PR) are then etched by plasma formed from the 
ionization of Ar gas particles in a vacuum of 6 × 10−7 Torr at 50W RF power for 2.5 min before the 
samples are treated with a chemical remover. Subsequently, the samples were placed in a chemical 
remover in an ultrasonic bath for ~1 h at 60 °C, the ultrasonic bath was turned off and the samples 
were left in the chemical remover for 15 h. The samples were then rinsed in di-ionised water and left 
to dry in a vacuum chamber for an hour. 
The second fabrication stage involves forming metallic Cr and Au electrodes as the source, drain 
and voltage electrodes. The electrode formation follows the same process as the graphene channel 
formation, but the samples are post-baked in an oven at 120 °C for 15 min instead of exposing to DUV 
on a hotplate. Next, Cr is thermally evaporated using an Edwards Thermal Evaporator. The Cr target 
was heated to ~2000 °C for 8 s in a vacuum pressure of 10−6 Torr to form a 5 nm layer of Cr on the 
graphene samples. Thermal evaporation is a gentle way of depositing Cr on the samples without 
destroying the graphene channels already formed, and the Cr layer functions as an adhesive layer 
between graphene and the Au metallic contacts [41]. Thirty nanometres of Au were sputtered directly 
on the Cr layer using Nordiko sputtering machine. The treatment with chemical remover was 
repeated and the samples were dried in a vacuum chamber for a further one hour. 
The fabricated 1cm x 1cm chips consists of 15 GFET devices, 5 asymmetric GFETs with the 
graphene channel length of 720 µm and 10 symmetric GFETs with graphene channel length of 400 
µm with both being 80 µm [41]. Figure 2 shows two symmetric GFET in series in a device (deployed 
in this study) and when they are with Clusterin at a concentration of 1 pg/mL. 
2.3. Functionalisation of GFETs 
The GFETs were functionalised by immobilising the graphene surface with an anti-Clusterin 
antibody using a linker molecule, after which bovine serum albumin (BSA) was deposited and the 
final step involved applying the Clusterin antigen in varying concentrations following the same 
protocol as Haslam, C. et al. [41]. Figure 3 illustrates the steps involved in the functionalisation 
process. 
The Pyr-NHS ester linker molecules are a cross-linking agent that react with special functionalised 
groups such as amino groups on proteins. The linker molecule (1-pyrenebutanoic acid succinimidyl 
ester) used belongs to N-Hydroxysuccinimide (NHS) group known as Pyr-NHS ester. It has an 
aromatic pyrenyl group that strongly interacts with the surface of graphene via non-covalent π-π 
interactions and the succinimidyl ester group covalently reacts with the amino group (NH2) of the 
antibody [42]. The linker molecule was applied at a concentration of 2mM and was allowed to 
incubate at −4 °C for 4 h, after which it was rinsed with PBS and allowed to dry in ambient 
temperature. Once dry, Raman and electrical characterisation was performed followed by the 
binding of anti-Clusterin antibody. The antibody (Ab) was applied at a concentration of 20 µg/mL 
and was allowed to incubate following the same procedure as for the linker stage. BSA was then 
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deposited on the GFET to block sites between the Ab regions preventing non-specific binding. BSA 
increases the tendency of the antibody to bind with the antigen of interest and it also improves the 
sensitivity of the sensor by decreasing background noise as the additional sites are blocked [43]. BSA 
was deposited at a concentration of 0.5% and allowed to incubate following the same procedure as 
for the linker and Ab stages. 
  
(a) (b) 
Figure 2. Graphene field effect transistor (GFET) devices; (a) symmetric GFET device with graphene 
channel length of 400 µm (symmetry by 3 voltage leads above and below the graphene channel). Here 
Ch-1T refers to channel 1 top voltage leads, Ch-lB refers to channel 1 bottom voltage leads and Ch-2B 
refers to channel 2 bottom voltage leads; (b) functionalised symmetric GFET device Clusterin 
(1pg/mL) with zoomed in inset of graphene channel and yellow dotted lines indicating the drop of 
solutions on the two series GFET channels (diameter of the drop region is ~900 µm). 
 
Figure 3. Steps for GFET functionalisation; (a) bare graphene; (b) annealed graphene (showing 
evaporation of water molecules); (c) attachment of Pyr-NHS ester molecules with graphene; (d) anti-
Clusterin antibody attachment to linkers (red); (e) bovine serum albumin (BSA) blocking (purple); (f) 
binding of Clusterin (tri-colour molecules) with the anti-Clusterin antibody. 
The final step involved depositing Clusterin antigen on the samples at varying concentrations 
from 1 pg/mL–100 pg/mL, followed by the samples being incubated for 1h at 37 °C before they were 
allowed to dry in ambient temperature and characterised using Raman spectroscopy and electrical 2-
probe and 4-probe measurements [44]. 
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3. Results 
Characterisation of GFETs 
The GFETs were characterised using Raman Spectroscopy to analyse the quality of the graphene 
channels [45] and also with a semiconductor device parameter analyser to determine the electrical 
properties of the GFETs. Raman Spectroscopy is one of the most accurate, effective and non-
destructive tool for the characterisation of graphene because of its sensitivity to important features 
and properties of graphene such as defect [46], doping [47], strain [48] and temperature [49]. The 
Raman spectrum of graphene is made up of three main features with different physical origins; they 
are the 2D peak previously known as G’ peak, the G peak and D peak. In monolayer graphene, the 
2D peak is observed at a Raman shift of ~2700 cm−1, the G peak at a Raman shift of ~1580 cm−1 and the 
D peak at a Raman shift ~1350 cm−1 [50,51]. Figure 4 shows Raman spectra of three devices after 
fabrication, the intensity ratio I(2D)/I(G) position for Ch-1T = ~ 1.10, Ch-1B = ~1.04 and Ch-2B = ~ 1.20 
and full width half maximum (FWHM) of the 2D peak for Ch-1T = 59.8 cm−1 , Ch-1B = 66.9 cm−1 and 
Ch-2B = 54.9 cm−1, which confirms the graphene channels are monolayer, and the D peak confirms 
the presence of defects, which is generally caused by the fabrication process. 
 
Figure 4. Raman Spectra of three monolayer graphene field-effect transistor (GFET) sensors after 
fabrication. 
The GFETs were electrically characterised using a Keysight B1500A semiconductor device 
parameter analyser interfaced to a Cascade probe station in ambient temperature and two-probe and 
a four-probe ID–VD and ID–VG measurements were taken to study the electrical properties and 
performance of the sensors such as its sheet resistance, contact resistance, Dirac curve and mobility. 
ID–VD measurements were taken on each sensor with a voltage sweep from −50 mV to +50 V and 
compliance of 100 µA. The sensors showed a linear response in current from changes in drain voltage, 
showing the channels are Ohmic as shown in the inset of Figure 5. Back-gated measurements were 
also performed to obtain the ID–VG curve with a forward and reverse voltage sweep from -100 V to 
+100 V, with a fixed drain voltage of 50 mV, Figure 5 (main panel). The ID–VG curves show the Dirac 
curve of the graphene channels, revealing that the three channels are hole doped. From the curves, 
the carrier mobility of the three channels is found to be around 500–600 cm2/Vs [52,53]. 
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Figure 5. Characteristic transfer curve ID–VG measurements of three graphene channels with 
corresponding output ID–VD curves (inset). Back-gated measurements showing forward and reverse 
sweep (from −100 V to 100 V) demonstrate the bare graphene channels are electrically almost identical. 
Table 1. The forward and reverse Dirac point voltages (DPV) and the resistance of the three channels. 
The Dirac point voltages reveal that the GFET is p-doped. Back-gate sweep rate was ~ 20V/s. 
Channel Forward Sweep DCV Reverse Sweep DCV Resistance 
Channel-1B 17 V 35 V 4086 Ω 
Channel-1T 35 V 22 V 3789 Ω 
Channel-2B 42 V 51 V 3852 Ω 
During the transfer of CVD graphene onto a substrate, a polymer Poly-methyl methacrylate 
(PMMA) is used to support the graphene while the Cu substrate is etched. The PMMA often leaves 
a layer of residue on the graphene surface and the residue remains on the surface even after 
fabrication. The standard process of removing PMMA using acetone does not completely remove the 
residues because of strong Van der Waals interaction with graphene [54]. The presence of the residue 
and also water molecules from the graphene surface degrade the transport properties of graphene, 
causing a weak p-doping [55]. We explored the effect of annealing to remove these contaminants 
from the surface of graphene, thermally annealing GFETs improve their performance increasing 
carrier mobility of the graphene channels [54,56,57]. We annealed the GFET at 215 °C for 30 min. 
Figure 4 shows results for Channel-1B at bare stage and after annealing. 
 
Figure 6. Comparison of the bare and annealed ID–VG curves with their corresponding ID–VD curves 
(inset). 
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After annealing, the resistance of the device decreased by 31% from ~4086 Ω to ~2822 Ω, and the 
carrier mobility increased by ~43% from 460 cm2/Vs to 660 cm2/Vs, improving the performance of the 
sensor. The annealed GFETs were then exposed to Pyr-NHS ester linker molecules using the drop-
cast method, as shown in Figure 2b where the diameter of the solution drop is typically ~ 1mm. The 
linker molecules were also characterised using absorbance spectra, which could easily resolve a 
concentration level of 0.2 µg/mL, as shown in Figure 7. The data show clear triple peaks in absorbance 
due to the pyrene moiety that is central to the Pyr-NHS ester linker molecules, also observed by Baek 
et al. [58] after functionalising carbon nanotubes for electrical detection of DNA hybridisation. The 
data in Figure 7 also show a repeat measurement (off-set for clarity) of the absorbance spectra over 
the 220–400 nm wavelength range, demonstrating excellent repeatability of the measurements. The 
independent absorbance spectra essentially served to increase our confidence in the linker solutions 
we deployed for the GFET sensor experiments. 
 
Figure 7. Absorbance spectra of Pyr-NHS ester linker molecules at 0.2 µg/mL concentration (red 
curve) and a repeat measurement (blue curve) off-set by 0.05 for clarity, showing the characteristic 
triple peaks due to the presence of pyrene moiety. 
Following the functionalization of the GFETs, Figures 8–10 show data from Channel-1B, 
Channel-1T and Channel-2B for ID versus VD output characteristic and ID versus VG transfer 
characteristic curves. Figure 8a,b shows data for bare to BSA functionalization stages, with ID–VD 
showing linear ohmic response and ID-VG showing shifts in the Dirac point from bare to linker stages. 
However, it is interesting to note the Dirac points seems to be above our 100 V limit of our 
measurement system for antibody to BSA stages. In contrast, although Figure 8c shows the standard 
ohmic response for functionalization stages from BSA to Clusterin and 100 ng/mL of human chorionic 
gonadotropin (hCG), whereas Figure 8d shows the Dirac point is approximately constant around 25 
V. This is in agreement with our previous observations [41] that the Dirac point shift is typically in 
the milli-volt region for similar concentrations of hCG. Figures 9 and 10 show almost identical 
response of the GFETs from bare to Clusterin antigen and hCG antigen detection. Table 2 shows the 
corresponding data from the GFET sensors from bare to Clusterin and hCG antigen stages based on 
the ID-VD results. 
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(a) (b) 
  
(c) (d) 
Figure 8. Characteristic curves for Channel-1B (a) ID–VD output curves for bare to BSA (b) ID–VG 
transfer curves for bare to BSA (c) ID–VD curves for BSA to human chorionic gonadotropin (hCG) 
(100ng) and (d) ID–VG curves for BSA to hCG (100ng) with off-set currents shown for clarity. Antigen 
concentrations are in units of g/mL. 
  
(a) (b) 
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(c) (d) 
Figure 9. Characteristic curves for Channel-1T (a) ID–VD output curves for bare to BSA (b) ID–VG 
transfer curves for bare to BSA (c) ID–VD curves for BSA to hCG (100 ng/mL) and (d) ID–VG curves for 
BSA to hCG (100 ng/mL), with off-set currents shown for clarity. Antigen concentrations are in units 
of g/mL. 
  
(a) (b) 
  
(c) (d) 
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Figure 10. Characteristic curves for Channel-2B (a) ID–VD output curve for bare to BSA (b) ID–VG 
transfer curve for bare to BSA (c) ID–VD curve for BSA to hCG (100 ng/mL) and (d) ID–VG curve for 
BSA to hCG (100 ng/mL), with off-set currents shown for clarity. Antigen concentrations are in units 
of g/mL. 
Channel Bare(Ω) 
Annealed 
(Ω) 
∆R% Linker (Ω) ∆R% 
Antibodies 
(Ω) 
∆R% 
BSA
(Ω) 
∆R
% 
Channel-1B 4086 2822 −31 1509 −47 1566 +3.8 1660 +6 
Channel-1T 3789 2422 −36 1660 −31 1936 +16 1775 −8 
Channel-2B 3852 2323 −35 1868 −20 1862 −0.3 1862 −2.4 
Mean+/-SD 
3909 ± 
128 
2522 ± 216 −34 ± 2 1679 ± 147 
−33 ± 
11 
1788 ± 160 6.5 ± 7 
1766 
± 83 
−1 ± 
6 
Table 2. The raw resistance and resistance change (%) at each stage of functionalisation for the three 
channels and the mean and standard deviation. The Clusterin and hCG concentrations are in units of 
g/mL. 
Channel 
Clusterin
(1pg)(Ω) 
∆R% 
Clusterin 
(10pg)(Ω) 
∆R% 
Clusterin 
(100pg)(Ω) 
∆R% 
hCG 
(100ng)(Ω) 
∆R% 
Channel-1B 3778  +127 4225 +11 5212  +23 4754  −9 
Channel-1T 4084 +130 4697 +15 5406 +15 5244 −2 
Channel-2B 3657 +101 3429 −6 4524 +32 4257 −6 
Mean+/-SD 
3840 ± 
180 
117 ± 13 4117 ± 523 7 ± 9 5047 ± 378 23 ± 7 4752 ± 403 −6 ± 3 
4. Discussion 
Figure 11 shows plots of percentage of resistance change (Mean ±SD) for each channel at all 
stages of the functionalization process. The data show that there is an approximate 30% reduction in 
resistance, from bare stage, when the channels are annealed. A further 30% reduction in resistance is 
observed when the linker molecules are bound to the graphene surface. In contrast, there is almost a 
negligible change in resistance when the antibodies and BSA interface with the linker functionalized 
GFETS. However, when 1pg/mL is drop-cast onto the GFETs, we observe an ~118% increase in 
resistance, as shown in the inset of Figure 11. We estimate a LoD ~210 fg/mL for Clusterin detection, 
similar to the LoD demonstrated for hCG detection by Haslam et al. [41] using our direct current 
four-probe electrical resistance (4PER) measurement technique. Table 3 shows a variety of biosensing 
platforms and detection techniques in comparison with our results reported here. 
We also tested the three GFET sensors for their specificity by introducing a three-orders-of-
magnitude higher concentration (compared to 100 pg/mL of Clusterin) hCG antigen at a 
concentration of 100 ng/mL; data are presented in Table 2 and a summary of the results is shown in 
Figure 11. The three sensors resulted in only an average of −6 ± 3% change in resistance, 
demonstrating the excellent specificity of our GFET sensors and the functionalization protocols. 
These highly promising results demonstrate the potential of our graphene sensors for low cost, 
repeatable performance, sensitivity and specificity for detecting a variety of other disease diagnosis 
also, such as cancer and cardiovascular (as the GFET sensors are generic transducers of biological to 
electrical signals) using a novel multiplexing platform we are currently developing, which will be 
reported in a future study. 
Commented [M6]: Please check if this table can be 
combined with the table below, if no, then please add a table 
caption for it. 
Commented [M7]: Please consider this suggested change. 
Commented [M8]: Is the bold necessary? 
Commented [M9]: Please consider this suggested change. 
Commented [M10]: Is the bold necessary? 
Proceedings 2020, 4, x FOR PEER REVIEW 12 of 16 
 
 
Figure 11. Plots of resistance change (Mean ± SD) for each functionalization stage with inset showing 
the corresponding percentage of resistance change relative to the previous stage (with bare stage 
being 0% by definition) (Mean ± SD). Note, the data in the inset for resistance change at 1 pg/mL 
Clusterin is reduced by a factor of 4 for clarity and Clusterin concentrations are in units of g/mL. 
Table 3. shows other approaches deployed for biosensors in comparison with our four-probe 
electrical detection technique. 
Electrode 
Materials 
Receptor System 
Detection 
Technique 
LoD 
(pg/mL) 
Ref. 
SPCE-NPAu 
SPCE-NPAu/Streptavidin/Biotin-Aβ-
42/anti-Aβ/anti-IgG-AP 
CV 
100 [59] 
Gold 
Nanoparticles 
GNP/MUA/NHS-EDC/Aβ(1-42) 
monoclonal antibody IgG/BSA/Aβ(1-42) 
peptide solution 
EIS 
1 [60] 
Magnetic 
Graphene 
Oxide 
Au/Avastin-MGO/VEGF DPV/CV 
31.25 [61] 
Au 
Nanoparticles 
Au/PSA antibody/BSA/PSA/tPSA SPR 
30 [62] 
SPCE 
SPCE/Pyr-NHS/anti-CLU 
F(ab’)2/BSA/CLU 
CV/SWV 
1 [63] 
SPR Chip-
Gold 
Gold film/EDC-NHS/anti-cTnT 
antibody/BSA/cTnT 
SPR 
500 [64] 
Gold 
nanoparticles 
Gold electrode/AuNP/MPA self-
assembly/EDC-NHS/BSA/HER2 
EIS 
500 [65] 
Graphite 
electrodes 
Electrode/EDC-NHS/anti-CA125,anti-
CA153,anti-
CEA/BSA/CA125,CA153,CEA/M-Pt-
CA125Ab2,M-Pt-CA153 Ab2,M-Pt-CEA 
Ab2 
DPV 
7 [66] 
PDMS/AuNP 
PDMS/AuNP/anti-human 
IgG(cTnI)/BSA/human IgG(cTnI) 
Colorimetric 
10 [67] 
GFET Graphene/Pyr-NHS/anti-CLU/BSA/CLU 4PER 
0.21 This 
work 
  
Commented [M11]: Is the bold necessary? 
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5. Conclusion 
We have reported the fabrication, functionalization and characterization of graphene FET 
sensors using Raman spectroscopy, four-probe electrical measurements and absorbance spectra 
using the highly collimated microbeam of Diamond B23 beamline for the detection of a prominent 
Alzheimer’s disease protein biomarker, Clusterin. The fabrication and functionalization protocols 
have enabled detection of Clusterin from 1 pg/mL to 100 pg/mL, with a limit-of-detection of ~210 
fg/mL. The GFET sensors were also found to have a repeatable performance over an extensive range 
of functionalization stages from bare to 100 pg/mL Clusterin concentration. In addition, the sensors 
were found to be highly specific, showing only a −6 ± 3 % resistance change compared to 100 pg/mL 
of Clusterin when a three-orders-of-magnitude higher concentration of hCG was applied (100 ng/mL) 
to the GFET sensors. Future work includes deploying the sensors to detect a panel of biomarkers for 
the early detection of Alzheimer’s disease (such as ApoE, Aβ, etc.) using a novel multiplexing 
platform we are currently developing, which will be reported in a future study. In addition, as the 
GFET sensors are generic transducers, we anticipate their future applications in a variety of other 
disease biomarker detection also, such as cancer and cardiovascular. 
Author Contributions: Conceptualization, S.A.A.; methodology, S.A.A., T.B., C.H., and B.O.; software, B.O. and 
T.B.; validation, S.A.A., T.B., G.S., and J.C.; formal analysis, S.A.A.; data curation, S.A.A.; writing—original draft 
preparation, S.A.A and T.B.; writing—review and editing, All; supervision, S.A.A.; T.W., and P.D.; project 
administration, S.A.A; funding acquisition, S.A.A. All authors have read and agreed to the published version of 
the manuscript. 
Funding: This research was funded by University of Plymouth (C.H.: GD105227-104, B.O’D.: GD110025-104), 
Diamond Light Source, DLS-SM24459-1 and EPSRC under contract number EP/M006301/1. 
Acknowledgments: We acknowledge Jeremy Clark (Materials & Structures), University of Plymouth, for usage 
of the optical microscope and LG Electronics for the supply of CVD graphene test samples. 
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the 
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to 
publish the results. 
References. 
1. Ji, A.G.; Wang, T.; Zhu, Z.G. Electric Field Effect in Atomically Thin Carbon Films. Science 2004, 306, 666–
669. 
2. Novoselov, K.S.; Jiang, D.; Schedin, F.; Booth, T.J.; Khotkevich, V.V.; Morozov, S.V.; Geim, A.K. Two-
dimensional Atomic Crystals. Proc. Natl. Acad. Sci. USA 2005, 102, 10451–10453. 
3. Bolotin, K.I.; Sikes, K.J.; Jiang, Z.; Klima, M.; Fudenberg, G.; Hone, J.E.; Stormer, H.L. Ultrahigh electron 
mobility in suspended graphene. Solid State Communications 2008, 146, 351–355. 
4. Morozov, S.V.; Novoselov, K.S.; Katsnelson, M.I.; Schedin, F.; Elias, D.C.; Jaszczak, J.A.; Geim, A.K. Giant 
Intrinsic Carrier Mobilities in Graphene and Its Bilayer.pdf. Phys. Rev. Lett. 2008, 100, 11–14. 
5. Castro Neto, A.H.; Guinea, F.; Peres, N.M.R.; Novoselov, K.S.; Geim, A.K. The Electronic Properties of 
Graphene. Rev. Mod. Phys. 2009, 81, 109–162. 
6. Balandin, A.A.; Ghosh, S.; Bao, W.; Calizo, I.; Teweldebrhan, D.; Miao, F.; Lau, C.N. Superior Thermal 
Conductivity of Single-Layer Graphene. Nano Lett. 2008, 8, 902–907. 
7. Blake, P.; Brimicombe, P.D.; Nair, R.R.; Booth, T.J.; Jiang, D.; Schedin, F.; Geim, A.K.  Graphene-Based 
Liquid Crystal Device. Nano Lett. 2008, 8, 1704–1708. 
8. Booth, T.J.; Blake, P.; Nair, R.R.; Jiang, D.; Hill, E.W.; Bangert, U.; Geim, A.K. Macroscopic Graphene 
Membranes and Their Extraordinary Stiffness. Nano Lett. 2008, 8, 2442–2446. 
9. Awan, S.A.; Lombardo, A.; Colli, A.; Privitera, G.; Kulmala, T.S.; Kivioja, J.M.; Ferrari, A.C. Transport 
conductivity of graphene at RF and microwave frequencies. 2D Mater. 2016, 3, 015010. 
10. Lin, Y.M.; Dimitrakopoulos, C.; Jenkins, K.A.; Farmer, D.B.; Chiu, H.Y.; Grill, A.; Avouris, P. 100-GHz 
transistors from wafer-scale epitaxial graphene. Science 2010, 327, 662–662. 
11. Bao, Q.; Loh, K.P. Graphene photonics, plasmonics, and broadband optoelectronic devices. ACS Nano 2012, 
6, 3677–3694. 
Proceedings 2020, 4, x FOR PEER REVIEW 14 of 16 
 
12. Wang, X.; Zhi, L.; Mullen, K. Transparent, Conductive Graphene Electrodes for Dye-Sensitized Solar Cells. 
Nano Lett. 2008, 8, 323–327. 
13. Wang, Y.; Shi, Z.; Huang, Y.; Ma, Y.; Wang, C.; Chen, M.; Chen, Y. Supercapacitor Devices Based on 
Graphene Materials. J. Phys. Chem. C 2009, 113, 13103–13107. 
14. Bunch, J.S.; Van Der Zande, A.M.; Verbridge, S.S.; Frank, I.W.; Tanenbaum, D.M.; Parpia, J.M.; McEuen, 
P.L. Electromechanical resonators from graphene sheets. Science 2007, 315, 490–493. 
15. Stankovich, S.; Dikin, D.A.; Dommett, G.H.; Kohlhaas, K.M.; Zimney, E.J.; Stach, E.A.; Ruoff, R.S. 
Graphene-based composite materials. Nature 2006, 442, 282–286. 
16. Justino, C.I.; Gomes, A.R.; Freitas, A.C.; Duarte, A.C.; Rocha-Santos, T.A. Graphene based sensors and 
biosensors. TrAC Trends in Analytical Chemistry 2017, 91, 53–66. 
17. Vu, C.A.; Chen, W.Y. Field-Effect Transistor Biosensors for Biomedical Applications: Recent Advances and 
Future Prospects. Sensors 2019, 19, 4212–22. 
18. Geim, A.K.; Novoselov, K.S. The Rise of Graphene. A Coll. Rev. Nat. J. 2010, 11–19, 
doi:10.1142/9789814287005_0002. 
19. Dong, X.; Shi, Y.; Huang, W.; Chen, P.; Li, L. J. Electrical detection of DNA hybridization with single-base 
specificity using transistors based on CVD-grown graphene sheets. Adv Mater. 2010, 22, 1649–53. 
20. Okamoto, S.; Ohno, Y.; Maehashi, K.; Inoue, K.; Matsumoto, K. Immunosensors Based on Graphene Field-
Effect Transistors Fabricated Using Antigen-Binding Fragment. Japanese Journal of Applied Physics 2012, 51, 
06FD08. 
21. Novoselov, K. S.; Geim, A. K.; Morozov, S. V.; Jiang, D.; Katsnelson, M. I.; Grigorieva, I.; Firsov, A. A. Two-
dimensional gas of massless Dirac fermions in graphene. Nature 2005, 438, 197–200. 
22. Society, A.S. Alzheimer’s Society: Facts for the Media. Available online: 
https://www.alzheimers.org.uk/about-us/news-and-media/facts-media (accessed on 9 September 2020). 
23. Iqbal, K.; Alonso, A. D. C.; Chen, S.; Chohan, M. O.; El-Akkad, E.; Gong, C. X.; Tanimukai, H. Tau pathology 
in Alzheimer disease and other tauopathies. Biochim. Biophys Acta 2005, 1739, 198–210. 
24. Selkoe, D.J. The Molecular Pathology of Alzheimer’s Disease. Neuron 1991, 6, 487–498. 
25. Glenner, G.G.; Wong, C.W. Alzheimer’s disease: Initial report of the purification and characterization of a 
novel cerebrovascular amyloid protein. Biochim Biophys Res. Comms. 1984, 120, 885–890. 
26. Masters, C.L. Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc. Natl. Acad. Sci. 
USA 1985, 82, 4245–4249. 
27. Hardy, J.; Selkoe, D.J. The Amyloid Hypothesis of Alzheimer’s Disease Progress on the Road to 
Therapeutics. Science 2002, 297, 353–356. 
28. De Silva, H. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high 
density lipoproteins. J. Biol. Chem. 1990, 265, 13240–13247. 
29. Satapathy, S. Extracellular chaperones in neuronal proteinopathies: Protecting and facilitating neuronal 
function. Cell Commun. Insights 2017, 9, 1–13. 
30. Lidström, A. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex 
in Alzheimer’s disease. Exp. Neurol. 1998, 154, 511–521. 
31. May, P.C. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer’s disease 
and in response to experimental lesions in rat. Neuron 1990, 5, 831–839. 
32. Ghiso, J. The cerebrospinal-fluid soluble form of Alzheimer’s amyloid β is complexed to SP-40, 40 
(apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 1993, 293, 27–30. 
33. Matsubara, E. Apolipoprotein J and Alzheimer’s amyloid β solubility. Biochem. J. 1996, 316, 671–679. 
34. Tsuruta, J. Structural analysis of sulphated glycoprotein 2 from amino acid sequence. Relationship to 
clusterin and serum protein 40, 40. Biochem. J. 1990, 268, 571–578. 
35. James, R. Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity 
with SP-40, 40, an inhibitor of complement-mediated cytolysis. Arterioscler. Thromb. J. Vasc. Biol. 1991, 11, 
645–652. 
36. Kirszbaum, L.; Bozas, S.; Walker, I. SP-40, 40, a protein involved in the control of the complement pathway, 
possesses a unique array of disulphide bridges. FEBS Lett. 1992, 297, 70–76. 
37. Thambisetty, M. Association of plasma clusterin concentration with severity, pathology, and progression 
in Alzheimer disease. Arch. General Psychiatry 2010, 67, 739–748. 
38. Oda, T. Purification and characterization of brain clusterin. Biochem. Biophys. Res. Commun. 1994, 204, 1131–
1136. 
Proceedings 2020, 4, x FOR PEER REVIEW 15 of 16 
 
39. Mayo Clinic: Dementia. 2020. Available online: https://www.mayoclinic.org/diseases-
conditions/dementia/diagnosis-treatment/drc-20352019 (accessed on 9 September 2020). 
40. Hussain, R.; Javorfi, T.; Siligardi, G. Circular dichroism beamline B23 at the Diamond Light Source. J. 
Synchrotron. Radiat. 2012, 19, 132–135. 
41. Haslam, C. Label-Free Sensors Based on Graphene Field-Effect Transistors for the Detection of Human 
Chorionic Gonadotropin Cancer Risk Biomarker. Diagnostics 2018, 8, 5. 
42. Huang, Y. Graphene-based biosensors for detection of bacteria and their metabolic activities. J. Mater. Chem.  
2011, 21, 12358–12362. 
43. Tips for Reducing ELISA background Life Science Articles 2012. Available online: 
https://www.biocompare.com/Bench-Tips/122704-Tips-for-Reducing-ELISA-Background/ (accessed on 12 
October 2020). 
44. Awan, S.A.; Kibble, B.; Schurr, J. Coaxial Electrical Circuits for Interference-Free Measurements; IET: London, 
UK, 2011. 
45. Ferrari, A.C. Raman spectrum of graphene and graphene layers. Phys. Rev. Lett. 2006, 97, 187401. 
46. Ferrari, A.C. Raman spectroscopy of graphene and graphite: Disorder, electron–phonon coupling, doping 
and nonadiabatic effects. Solid State Commun. 2007, 143, 47–57. 
47. Casiraghi, C. Raman fingerprint of charged impurities in graphene. Appl. Phys. Lett. 2007, 91, 233108. 
48. Huang, M. Phonon softening and crystallographic orientation of strained graphene studied by Raman 
spectroscopy. Proc. Natl. Acad. Sci. USA 2009, 106, 7304–7308. 
49. Calizo, I. Temperature dependence of the Raman spectra of graphene and graphene multilayers. Nano Lett.  
2007, 7, 2645–2649. 
50. Graf, D. Spatially resolved Raman spectroscopy of single-and few-layer graphene. Nano Lett. 2007, 7, 238–
242. 
51. Mafra, D. Determination of LA and TO phonon dispersion relations of graphene near the Dirac point by 
double resonance Raman scattering. Phys. Rev. B 2007, 76, 233407. 
52. Zhong, H. Comparison of mobility extraction methods based on field-effect measurements for graphene. 
AIP Adv. 2015, 5, 057136. 
53. Bøggild, P. Mapping the electrical properties of large-area graphene. 2D Mater. 2017, 4, 042003. 
54. Cheng, Z. Toward intrinsic graphene surfaces: A systematic study on thermal annealing and wet-chemical 
treatment of SiO2-supported graphene devices. Nano Lett. 2011, 11, 767–771. 
55. Lin, Y.C. Graphene annealing: How clean can it be? Nano Lett. 2012, 12, 414–419. 
56. Kumar, K.; Kim, Y.-S.; Yang, E.-H. The influence of thermal annealing to remove polymeric residue on the 
electronic doping and morphological characteristics of graphene. Carbon 2013, 65, 35–45. 
57. Pirkle, A. The effect of chemical residues on the physical and electrical properties of chemical vapor 
deposited graphene transferred to SiO2. Appl. Phys. Lett. 2011, 99, 122108. 
58. Baek, Y.-K. Label-Free Detection of DNA Hybridization Using Pyrene-Functionalized Single-Walled 
Carbon Nanotubes: Effect of Chemical Structures of Pyrene Molecules on DNA Sensing Performance. J. 
Nanosci. Nanotechnol. 2011, 11, 4210–4216. 
59. Rama, E.C.; González-García, M.B.; Costa-Garcia, A. Competitive electrochemical immunosensor for 
amyloid-beta 1-42 detection based on gold nanostructurated Screen-Printed Carbon Electrodes. Sens. 
Actuators B Chem. 2014, 201, 567–571. 
60. Wu, C.-C. Electrochemical impedance spectroscopy analysis of A-beta (1-42) peptide using a 
nanostructured biochip. Electrochim. Acta 2014, 134, 249–257. 
61. Lin, C.-W. A reusable magnetic graphene oxide-modified biosensor for vascular endothelial growth factor 
detection in cancer diagnosis. Biosens. Bioelectron. 2015, 67, 431–437. 
62. Uludag, Y.; Tothill, I.E. Cancer biomarker detection in serum samples using surface plasmon resonance 
and quartz crystal microbalance sensors with nanoparticle signal amplification. Anal. Chem. 2012, 84, 5898–
5904. 
63. Islam, K. Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer’s Biomarker. 
Sensors 2018, 18, 308. 
64. Pawula, M.; Altintas, Z.; Tothill, I.E. SPR detection of cardiac troponin T for acute myocardial infarction. 
Talanta 2016, 146, 823–830. 
65. Chun, L. Electrochemical detection of HER2 using single stranded DNA aptamer modified gold 
nanoparticles electrode. Sens. Actuators B Chem. 2013, 186, 446–450. 
Proceedings 2020, 4, x FOR PEER REVIEW 16 of 16 
 
66. Cui, Z. Ultrasensitive electrochemical immunosensors for multiplexed determination using mesoporous 
platinum nanoparticles as nonenzymatic labels. Anal. Chim. Acta 2014, 807, 44–50. 
67. Wu, W.-Y. PDMS gold nanoparticle composite film-based silver enhanced colorimetric detection of cardiac 
troponin I. Sens. Actuators B: Chem. 2010, 147, 298–303. 
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional 
affiliations. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
